Polynucleotides encoding IL-17/IL-23 bispecific, IL-17A/F and IL-23p19 antibodies

US9783606B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Brenda L. Stevens · Seattle, US
• Alison Witte · Scotts Valley, US
• Mark W. Rixon · Seattle, US
• Josephine M. Cardarelli · Redwood City, US
• Thomas D. Kempe · Sunnyvale, US
• Scott R. Presnell · Tacoma, US
• Mohan Srinivasan · Cupertino, US
• Susan WONG · Fremont, US
• Guodong Chen · East Brunswick Township, US
• Hui Wei · Princeton Junction, US
• Stanley Krystek · Ringoes, US
• Lumelle Schneeweis · Sparta, US
• Paul O. Sheppard · Granite Falls, US
• Indrani Chakraborty · Fremont, US

Key dates

• Filing date: Dec 19, 2014
• Grant date: Oct 10, 2017
• Expiry date: Dec 19, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.